Reports FY22 revenue $140.10K, consensus $120K."We have made significant progress across our pipeline this past year and have amassed additional and significant data supporting the disease modifying potential of our allosteric GCase regulators in Parkinson’s and Gaucher disease models," said Matthias Alder, Chief Executive Officer. "We look forward to commencing the clinical program for GT-02287 with the submission of the dossier for the Phase 1 clinical trial by mid-2023. We are also pleased with the grant funding supporting the research program in Alpha-1 Antitrypsin Deficiency, which validates the versatility of our SEE-Tx platform and the new approach to address AAT deficiency-related metabolic diseases with allosteric small molecule regulators."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on GANX:
- Gain Therapeutics Reports Full Year 2022 Financial Results and Business Update
- Gain Therapeutics announces grant award by Eurostars with Innosuisse
- Gain Therapeutics Announces Grant Award by Eurostars with Innosuisse for Alpha-1 Antitrypsin Deficiency Research Program
- Gain Therapeutics to Participate in the Oppenheimer 33rd Annual Healthcare Conference
- Gain Therapeutics presents preclinical data from Gaucher Disease Program